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1. Introduction
A moderately built 25-year-old female with a 24-week pregnancy and per-vaginal bleeding is brought
to the operation theatre in the wee hours of the morning for suction evacuation. Her medical and surgical
histories are unremarkable. She is highly irritable and moderately pale. She has a pulse rate of 156 beats
per minute, blood pressure of 110/80 mm of Hg, respiratory rate of 32 breaths per minute and mild pedal
oedema. Her haemoglobin level is 8 gm/dl. Her thyroid function tests are markedly deranged showing
severe biochemical hyperthyroidism (SerumT3– 6.46 mmol/L, T4 – 470 nmol/L and TSH – 0.03 μ IU/
ml). The serum β hCG levels are markedly raised. An ultra-sonogram shows signs of a complete molar
pregnancy.
This is a typical presentation of gestational trophoblastic disease with trophoblastic hyper‐
thyroidism.
Gestational trophoblastic disease includes a group of pregnancy-related tumours called
trophoblastic tumours. These include hydatidiform mole and choriocarcinoma. Hyperthyr‐
oidism is a rare complication of gestational trophoblastic disease. It is called trophoblastic
hyperthyroidism.
2. Gestational trophoblastic disease
The abnormal proliferation of trophoblastic tissue in the developing human placenta results
in the condition known as Gestational Trophoblastic Neoplasia [1,2]. Gestational Trophoblastic
Neoplasia lesions are histologically distinct malignant lesions that include hydatidiform mole,
choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour.
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Gestational Trophoblastic Neoplasia often arises after molar pregnancy. It can also occur after
any gestation including miscarriages and term pregnancies [2].
Gestational trophoblastic disease is a family of diseases that includes complete and partial
molar pregnancy also known as hydatidiform mole, locally invasive or Disseminated chorio‐
carcinoma and placental site trophoblastic tumour [3]. Placental site trophoblastic tumour,
invasive mole and choriocarcinoma are termed Gestational Trophoblastic Tumours. They are
malignant while hydatidiform mole is a benign form of Gestational Trophoblastic Disease [4].
2.1. Classification of gestational trophoblastic disease (FIGO) (International Federation of
Gynaecology and Obstetrics) [5]
Hydatidiform mole-
• complete
• partial
Gestational Trophoblastic Neoplasia-
• Invasive mole
• Choriocarcinoma
• Placental site trophoblastic tumor
• Epithelioid trophoblastic tumor
2.2. Hydatidiform mole
It is an abnormal condition of the ovum where there are partly degenerative and partly
hyperplastic changes in the young chorionic villi. These result in the formation of clusters of
small cysts of varying sizes. Because of its superficial resemblance to hydatid cyst, it is named
as hydatidiform mole and the pregnancy associated with it is known as molar pregnancy. It
is best regarded as a benign neoplasia of the chorion with malignant potential [6].
Molar pregnancy is common in Oriental countries – Philippines, China, Indonesia, Japan and
India as also in Africa and Central and Latin America [6]. The incidence of molar pregnancy
has been reported to range between 0.5 and 2 to 2.5 per one thousand pregnancies [7,8,9]. In
some Asian countries, the incidence is as high as 1 in 82 pregnancies [1]. The highest incidence
is in Philippines being 1 in 80 pregnancies and lowest in European countries, North Ameri‐
ca,Australia and New Zealand [6,10]. In the United States,hydatidiform moles are observed in
approximately 1in 600 therapeutic abortions and 1 in 1000-2000 pregnancies [2,11]. The
incidence in India is about 1 in 400 pregnancies [12]. In Nepal, the incidence of gestational
trophoblastic disease as per records from different hospitals is 5.1,2.9,2.8and 4.1 per 1000 live
births [13].The incidence of hydatidiform mole in the Middle East is 1:60 to 1:500 [14].
Molar pregnancies develop as a result of abnormal fertilisation [6]. Risk factors for developing
a molar pregnancy include advanced maternal age, teen age, inadequate nutrition, disturbed
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maternal immune mechanisms, cytogenetic abnormality, environmental factors and a history
of hydatidiform mole [1]. Although most molar pregnancies are sporadic, a familial syndrome
of recurrent hydatidiform mole has been described and first reported in 1980, suggesting an
autosomal recessive inheritance pattern [15,16].
2.2.1. Pathology of hydatidiform mole [6]
Naked eye appearance. (fig 1)
The mass in the uterus is made of multiple chains and clusters of cysts of varying sizes from
a pin head to that of a large grape. The embryo and amniotic sac may or may not be seen. Red
areas may be seen suggesting haemorrhage in the decidual space [6] (fig 1)
Figure 1. Gross appearance of hydatidiform mole
Microscopic appearance
The villus pattern is distinctly maintained. The vesicles are filled with interstitial fluid that is
almost similar to ascitic or oedema fluid but rich in hCG. There are no blood vessels.
2.2.2. Clinical features of hydatidiform mole
The  traditional  presenting  features  include  vaginal  bleeding,  excessive  uterine  size,
hyperemesis gravidarum, theca lutein cysts and preeclampsia in early pregnancy [17,18].
The clinical presentation has significantly changed in the past years [19].Modern facilities
like ultrasonography and serum alpha hCG help early diagnosis even before any signs and
symptoms appear [20].
Trophoblastic Hyperthyroidism and Its Perioperative Concerns
http://dx.doi.org/10.5772/57523
245
Symptoms: [6]
1. Vaginal bleeding – It may be mixed with fluid from the ruptured cysts giving the
appearance of ‘white currant in red currant juice’.This is the most common symptom,
being present in about 70-90% cases. [19]
2. Lower abdominal pain-This is due to infection, uterine perforation or uterine contractions.
3. Constitutional symptoms – Patient appears sick, has excessive vomiting, breathlessness,
thyrotoxic features like tremors, palpitations, anxiety, weight loss and increased appetite.
4. Expulsion of grape-like vesicles per vaginum.
Signs: [6]
1. Signs of early pregnancy.
2. Patient looks very ill.
3. Prominent pallor out of proportion to blood loss.
4. Features of toxaemia (hypertension, oedema and proteinuria) are present in about 50% of
cases. Rarely convulsions may occur.
5. Per abdomen –
a. The size of uterus is more than expected for the period of amenorrhoea.
b. The uterus feels firm and elastic(doughy) because of the absence of amniotic fluid
sac.
c. Foetal parts are not felt; absence of foetal movements.
d. Absent foetal heart sounds.
6. Per vaginum-
a. Internal ballotment cannot be elicited.
b. Unilateral or bilateral enlarged palpable ovaries are seen in 25-50% of cases.
c. Vesicles are seen in vaginal discharge.
2.2.3. Investigations and diagnosis
1. Serial quantitative estimation of hCG-The hallmark of diagnosing hydatidiform mole is
a positive β-hCG urine assay pregnancy test [18]. High hCG titre in urine diluted up to 1
in 200 to 1 in 500 beyond 100 days of gestation is very suggestive [6]. A retrospective
analysis of molar pregnancies reported that 75% of patients present with vaginal bleeding,
while 54% presented with enlarged uterus for gestational dates and 100% had excessively
elevated β-hCG levels [18]. Qualitative β-hCG urine assays may be misleading in molar
pregnancy. There have been reports of false negative both, urine and serum β-hCG
pregnancy tests in hydatidiform mole [18].
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Christopher and Ladde reported a case of a molar pregnancy presenting with abdominal pain and vaginal
spotting with multiple false negative urinary pregnancy tests. The laboratory qualitative urine β-hCG
assays were negative. As she was being prepared for transport to the ultrasound suite, she discharged a
large, fleshy vesicular mass followed by profuse vaginal bleeding. They attributed this to the fact that
qualitative β-hCG assays like sandwich chromatography immunoassays may produce false negative
results in a phenomenon known as the high dose hook effect [18].
2. Ultrasonography-The characteristic ‘snowstorm appearance’ is seen (fig 3).
2.2.4. Types of hydatidiform mole – Molar pregnancies are categorised as complete or partial
Complete moles have diploid karyotype of solely paternal origin [18]. In a complete molar
pregnancy, the placenta becomes oedematous secondary to grossly enlarged hydropic
chorionic villi and in most cases the foetus, cord and amniotic membranes are absent [1]. The
traditional presenting features like vaginal bleeding, excessive uterine size, hyperemesis
gravidarum, hyperthyroidism, theca lutein cysts and preeclampsia in early pregnancy are
present [17,18]. Patients with a complete molar pregnancy have excessively high levels of
serum and urinary hCG resulting from trophoblastic proliferation [1]. hCG serves as a marker
for the tumour.The diagnosis is made by ultrasonogram demonstrating a snowstorm appear‐
ance without a foetus (fig 3) [7].
Partial moles have triploid karyotype of both maternal and paternal origin. Partial molar
pregnancies account for 10% of all hydatidiform moles [1]. In partial mole, there will be some
identifiable foetal tissue(fig 2). Sanchez-Ferrer ML et al have described an extremely rare case
of a partial hydatidiform mole with a normal fetus [21]. The classic clinical presentation
described for complete mole is rare in partial mole and significant hCG level elevation is less
common [15].Ultrasonography will not show the classical snow-storm appearance (fig 3). Most
often the diagnosis is made upon histological review of curettage specimens [15].
Figure 2. Specimen of partial mole.
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Figure 3. Transabdominal ultrasonogram showing‘snowstorm’ appearance of a complete mole in the uterus.
2.3. Complications of molar pregnancy
2.3.1. Immediate
Surgical [6]
1. Haemorrhage and shock – due to separation of vesicles or uterine perforation.
2. Sepsis – due to surgery and presence of degenerated vesicles and blood.
3. Uterine perforation – due to perforation by the mole or during surgery.
Medical
Eighty percent of cases of molar pregnancy are uncomplicated and twenty percent are
associated with an extensive list of medical complications like hyperthyroidism, severe
anaemia, haemorrhage, trophoblastic embolisation and pregnancy induced hypertension,
some of which may be of a critical nature [1,12,22].
2.3.2. Late
18-28% of patients with complete mole and 2-4% of patients with partial mole can develop
persistent neoplasia or post molar gestational trophoblastic neoplasia [15]. The development
of choriocarcinoma following hydatidiform mole ranges from 2-10% [6].
2.4. Management of hydatidiform mole [6]
The principles are:
1. To give adequate supportive therapy to restore blood volume.
2. To evacuate the uterus as soon as diagnosis is made. Complete evacuation of the uterus
is made by suction evacuation [1,12]. Hysterotomy is done in case of very low general
condition of the patient or profuse vaginal bleeding. Hysterectomy is done in patients
having three or more children or if patient’s age is more than 35 years.
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Suction dilatation and evacuation-Suction dilatation and evacuation is a safe, rapid and
effective method for evacuating hydatidiform moles [23,24]. If the patient has already started
to expel the mole, the process is hastened by starting an oxytocin drip of 10-20units. The
products can then be rapidly evacuated either digitally or with the help of suction cannula [25].
If the process of expulsion of mole has not started, then a definitive plan for uterine evacuation
is made. The cervix is dilated gently and slowly [19].If necessary,prostaglandin gels can be
introduced into the cervix to promote cervical softening and dilatation [25].Light and careful
curettage should be performed following the suction procedure to ensure complete evacuation
of the uterine content [19].The use of a bedside ultrasound unit at the time of the procedure
will ensure complete evacuation of uterine contents [23].
3. Prophylactic chemotherapy with oral methotrexate for 3 courses of 5 days each.
2.5. Invasive mole
The villus structure is maintained as in hydatidiform mole but the uterine wall may be
perforated in multiple areas (fig 4). Distant metastasis can occur via blood stream to lungs,
vagina or brain. The treatment is hysterectomy followed by cytotoxic therapy [6].
Figure 4. Specimen of an invasive mole
2.6. Choriocarcinoma
The incidence is 1 in 5000 pregnancies in Oriental countries and 1 in 50,000 in Europe and
North America. 50% of cases occur after molar pregnancies. The villous pattern of hydatidi‐
form mole is lost here and invasion of uterine wall accompanied by necrosis and haemorrhage
is seen.(fig 5) Distant metastases can occur to lungs(70%), anterior vaginal wall(50%),
brain(10%) and others [6]. Treatment is done with– [2,6]
1. Cytotoxic drugs.
2. Hysterectomy and cytotoxic drugs.
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3. Adjuvant procedures like brain irradiation for cerebral metastasis, craniotomy in cerebral
metastasis, hepatic resection to control bleeding from hepatic metastasis and vaginal
packing for bleeding from vagina.
Figure 5. Specimen of choriocarcinoma of the uterus
2.7. Cytotoxic drugs in Gestational Trophoblastic Neoplasias [2]
Gestational Trophoblastic Neoplasias are highly responsive to chemotherapy. Early stage
Gestational Trophoblastic Neoplasia is often cured with single agent chemotherapy. Advanced
stage requires multiple agent combination regimens. EMACO (Etoposide, Methotrexate,
Actinomycin-D, Cyclophosphamide and Vincristine) is the most commonly used regimen for
stage IV tumours. MAC regimen with Methotrexate,Actinomycin-D and Cyclophosphamide
is also used.
3. Relationship between hCG and thyroid
hCG is a placental glycoprotein. Its levels are high in the first trimester of pregnancy. It
shares some structural similarity with TSH [26,27] (fig6). It is composed of alpha and beta
subunits,  non covalently linked.  The alpha subunit  is  identical  to  that  found in TSH. It
consists of a 92 aminoacid chain containing two nitrogen linked oligosaccharide side chains
[3].  The beta subunit of hCG consists of 145 aminoacid residues with two N linked and
four O linked oligosaccharides. The beta subunit of TSH is composed of 112 residues and
one N linked oligosaccharide [28]. TSH and hCG thus share a molecular mimicry and have
similar effects on the thyroid [29]. Nonetheless, hCG receptors share 45% homology with
the TSH receptors [3].
Several data indicate that hCG is a weak human thyrotropin [30]. In 1967, Burger reported that
impure, commercial hCG had thyroid stimulating activity in a mouse bioassay [31]. Bioassays
in mice, rats, chicks show that hCG stimulates iodine uptake, activates adenylate cyclase and
increases DNA synthesis in cultured rat thyroid cells [32]. It also activates the TSH receptor.
But the relative potency of hCG for the TSH receptor is 4000 times less than TSH [3]. It has
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been calculated that hCG contains approximately 1/4000th of the thyrotropic activity of human
TSH. In bioassays, hCG is only about 1/10000th as potent as human TSH during normal
pregnancy [33]. High circulating levels of hCG with their TSH like activity in the first trimester
of pregnancy may result in a slightly low TSH and an increase in free T4 concentration. hCG
may stimulate maternal T4 secretion [34]. It is estimated that an increment of hCG of
10,000UL-1 results in an increase of free T4 of 0.6pmolL-1 and a decrease in TSH of 0.1mUL-1
[35].Braunstein and Hershman reported that there was an inverse relationship between TSH
and hCG at about 10-12 weeks of pregnancy, the time of peak hCG levels [36]. Harada showed
an increase of free T4 and free T3 associated with the peak hCG [37,38].Serum TSH levels
particularly between 7 and 12 weeks of gestation fall to a nadir and present a mirror image
with peak hCG values.(fig 7) The lower normal TSH limits in first trimester is approximately
0.03-0.08 mIUL-1 secondary to the thyrotropic activity of hCG [7].
Highly purified standard hCG has only trivial TSH like activity [39,40]. Certain fractions of
hCG have greater TSH like activity than others [35]. The thyrotropic activity of hCG is
influenced by the number and structure of its oligosaccharide side chains. Deglycosylation
and partial desialation (removal of sialic acid) of β subunit of hCG enhances its thyrotropic
potency in rat thyroid cells [41]. Nevertheless, the circulating hCG patterns are different at
various stages of gestation [42]. HCG with reduced sialic acid content is increased in pregnant
patients with hyperthyroidism [40]. Partially desialated hCG has the greatest TSH like activity
and is often increased in molar pregnancy [35].
The development of hyperthyroidism due to hCG is largely influenced by the level of hCG.
Clinically  measurable  changes  in  thyroid  hormone concentration  are  only  likely  if  hCG
levels are around 50,000-70,000 mIUL-1 or more [35]. Extremely high levels are required for
the development of clinical hyperthyroidism. Case studies have indicated that, serum levels
of hCG of >100,000 mIUL-1 are usually needed to produce clinical evidence of thyrotoxico‐
sis [3]. Such high levels are seen in conditions like hyperplacentosis, hyperemesis gravida‐
rum, gestational trophoblastic disease, multiple pregnancy and hyper reaction-luteinalis [7].
These conditions are associated with the clinical  entity known as ‘transient non autoim‐
mune hyperthyroidism in early pregnancy’ wherein hCG is the main mediator of hyperthyr‐
oidism [7].
Figure 6. hCG molecular structure and major pituitary TSH glycoforms
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Figure 7. The pattern of serum TSH and HCG changes are shown as a function of gestation age. Between 8 and 14
weeks gestation, changes in serum hCG and TSH are mirror images of each other, and there is a significant negative
correlation between the individual TSH (nadir) and peak hCG levels.
4. Epidemiology of hyperthyroidism in gestational trophoblastic disease
Concomitant biochemical thyroid disease in patients with gestational trophoblastic disease is
relatively common [3]. Although hyperthyroidism has been reported more frequently in
women with a hydatidiform mole than in those with choriocarcinoma, there have been many
reports of hyperthyroidism in women with choriocarcinoma as well as a few men with
testicular tumours [28].
The prevalence of hyperthyroidism in patients with hydatidiform mole and choriocarcinoma
has been reported to be as high as 25-64% [28]. Hyperthyroidism develops in 5-10% cases of
molar pregnancy and an incidence up to 30% is reported in India [43]. The prevalence of
hyperthyroidism during complete molar pregnancy is as high as 7% [43]. In a study, 30 of 52
patients with gestational trophoblastic neoplasia were found to be thyrotoxic. The New
England Trophoblastic Disease Centre estimated that 20% of women with complete moles have
hyperthyroidism [28]. But in the same centre, between 1988 and 1993, none of 74 patients with
complete mole demonstrated evidence of hyperthyroidism [15].Biochemical hyperthyroidism
has been reported in a patient with a dichorionic pregnancy with one viable foetus and a
hydatidiform mole [44].
Clinical hyperthyroidism is found in approximately 5% of women with a hydatidiform mole
[26]. Clinical thyrotoxicosis is rare in molar pregnancy [45]. Clinical thyrotoxicosis is even more
rare in patients with partial mole. The first such case was reported in 2008 [46].Rarely the
thyroid stimulation can have potentially life threatening consequences [3]. The prevalence of
thyrotoxicosis in patients with trophoblastic tumors was reported to be close to 50% in some
older studies [7,47]. But nowadays with the ability of early detection of the disease, the
incidence is much lower.
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5. Aetiology of hyperthyroidism in molar pregnancy
Historically,  the first  association between hyperthyroidism and a product of  the tropho‐
blast was noted in patients with trophoblastic tumours [28]. In 1971, Hirshman and Higgins
reported  two  case  of  severe  hyperthyroidism  in  patients  with  hydatidiform  mole  and
demonstrated for  the  first  time thyrotropic  activity  in  molar  tissue [48].  This  stimulator
differed  biologically  and  immunologically  from  the  other  three  human  stimulators  i.e.
pituitary thyrotropin, chorionic thyrotropin found in normal pregnancies and the LATS in
Grave’s  disease  [7].  They  speculated  that  an  excessive  amount  of  the  extracted  molar
stimulator was responsible for the hyperthyroidism in both people [7].Hyperthyroidism in
patients with molar pregnancy is thought to occur as a manifestation of excessive levels of
circulating hCG which has a weak intrinsic thyroid stimulating activity, or from a thyrotro‐
pin like substance released from the mole [1,33,43].
Extremely high levels of hCG are typically required for the development of clinical hyper‐
thyroidism as the relative potency of hCG for the TSH receptor is relatively low [3].HCG levels
always exceed 300 IUml-1 in patients with hyperthyroidism caused by trophoblastic disease
[41]. The hCG levels are particularly high at 10-14 weeks of gestation in trophoblastic disease
[44]. In gestational trophoblastic disease, high levels of hCG cause activation of the thyrotropin
receptor and stimulate supraphysiological secretion of thyroid hormone [44]. The level of
thyroid stimulation is directly proportional to the hCG concentration [3]. Lemon et al studying
thyroid function in trophoblastic diseases reported a high correlation between levels of hCG
and TSH measured by radio-immunoassay secondary to cross-sensitivity of TSH and hCG
with the antibody they used [49]. None of their patients were clinically hyperthyroid and there
was poor correlation between hCG and T3 or T4 levels although high levels of thyroid hormone
occurred only at hCG levels greater than 100,000mIU/ml. Basic isoforms of hCG with high
bioactivity-immunoactivity ratio may be responsible for hyperthyroidism in some patients
with trophoblastic disease [28]. Nevertheless, the hCG molecule from women with tropho‐
blastic diseases has been found to display enhanced thyrotropic activity [50].
Some studies have however, revealed no significant relationship between elevation of serum
hCG  and  abnormally  high  values  of  free  thyroxine  index  in  patient  with  trophoblastic
tumors. These studies suggest that a substance distinct from hCG and elaborated by the
gestational trophoblastic tissue is responsible for thyrotoxicosis observed in patients with
trophoblastic  tumours.The  molar  thyrotropin  existing  in  the  serum  of  patients  with  a
hydatidiform mole differs from hCG by its larger molecular size and the duration of action,
which is longer [33,43,51].
6. Spectrum of biochemical abnormalities in trophoblastic
hyperthyroidism
1. The level of thyroid stimulation is directly proportional to hCG concentration and hence
the severity of clinical hyperthyroidism reflects the hCG level in gestational trophoblas‐
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tic disease. In patients with molar hyperthyroidism, serum hCG levels usually exceed
300U/ml and always exceed 100 U/ml. Patients with clinical evidence of thyrotoxico‐
sis may have serum levels of hCG of >100,000 mIU/L. However, some patients with
trophoblastic tumors with very high serum hCG levels do not manifest hyperthyroid‐
ism [3,28].
2. In patients with molar pregnancy, evidence for pronounced hypersecretion of T4 is
present. Hence, elevated serum free T4 & T3 levels are found [47].
3. A pattern of high values of serum protein bound iodine(PBI) and serum tri-iodothyronine
reaction(T3test)and relatively low values of serum cholesterol have been seen in most
patients with hydatidiform mole [52].
4. Pronounced increase in urinary P/C ratio occurs in patients with molar pregnancy
suggesting that they are hypermetabolic [47].
5. Dowling, Ingbar and Freinket were the first to note the occurrence of striking abnormal‐
ities in several aspects of thyroid economy in patients with molar pregnancy. They found
marked increases in serum PBI, PB131I, butanol-extractable 131I, thyroidal 131I uptake and
absolute iodine uptake(AIU) in the patients [53]
6. In some cases, even when serum free T4 and T3 concentrations were only slightly elevated,
serum TSH concentrations were low and serum TSH responses to TRH were low [28].
7. Several patients of trophoblastic tumors demonstrated thyroid hyperfunction or marked
increases in serum PBI but failed to display signs or symptoms of frank thyrotoxicosis [47].
7. Comparison of trophoblastic hyperthyroidism with other types of
hyperthyroidism and with the thyroid economy of normal pregnancy
[28,47]
1. Patients with trophoblastic hyperthyroidism have higher serum T4/T3 ratiosthan patients
with Grave’s hyperthyroidism.
2. Thyroid stimulating immunoglobulin is not detectable in trophoblastic hyperthyroidism
unlike Grave’s Disease.
3. Several of the changes in certain aspects of thyroid economy which occur in molar
pregnancy resemble superficially those seen in normal pregnancy. These include the
increase in thyroidal 131I uptake and serum PB131I; inpatients with molar pregnancy,
however, these indices tend to be more markedly increased.Values for serum PBI and
T4 concentration in molar pregnancy are usually much greater than in normal pregnancy.
4. In patients with the usual varieties of hyperthyroidism, the absolute concentration of free
T4 in serum is usually quite elevated as a result of increase in both: the total concentration
of T4 in serum and the free proportion. In patients with molar pregnancy, a smaller increase
in concentration of free T4 is generally seen since the proportion of free T4 is subnormal.
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5. Trophoblastic tumours secrete less oestrogen than normal placental tissue so that the
increase in serum thyroxine-binding globulin (TBG) concentration is less in molar
pregnancy than in normal pregnancy.
8. Some biochemical case profiles of trophoblastic hyperthyroidism
There is a spectrum of thyroid function abnormalities in gestational trophoblastic neoplasias
and thyroid function in an individual patient is determined by the relative influence of the
thyroid stimulator, nonthyroidal illnesses and the pregnancy [54].
1. In a study of the thyroid status of 27 African patients with gestational trophoblastic
neoplasia, 15 patients were found to be biochemically hyperthyroid. Of the 15 patients, 9
were clinically thyrotoxic. It was found that when serum levels of hCG reached a level of
about 0.1x106IU/L, 13 of 16 patients were biochemically hyperthyroid; at serum levels of
0.3x106IU/L of hCG, most patients were clinically thyrotoxic. T4 was invariably raised in
these patients but the T3:T4 ratios tended to be low(0.015 ± 0.005);rT3:T3 ratios were high
and TSH levels were not raised [55].
2. In 7 patients with metastatic trophoblastic disease, there was laboratory evidence of
increased thyroid function but clinical hyperthyroidism was either not present or minimal
and thyroid gland size was normal. There was uniform elevation of 24 hour radioiodine
uptake, serum PBI, BMR and the serum cholesterol was depressed [56].
3. In a study on 47 patients with hydatidiform mole, only 1 was found to be clinically
hyperthyroid, although 10 had serum total thyroxine values exceeding those found in
normal pregnancy(8 to 17 μ gm/dl). Among 34 patients in whom free thyroxine indices
could be calculated, 18 had elevated values for the free thyroxine index(>10.6), and 9 had
elevated values for total thyroxine and free thyroxineindex [57].
4. An 131I –tracer test performed in a patient with molar pregnancy indicated a very high
thyroidal 131I uptake, conversion ratio and thyroidal 131I secretion rate [58].
5. Studies on 11 patients were done before and after removal of a molar pregnancy. Before
evacuation of the mole, all patients demonstrated moderately to greatly elevated values
for thyroidal 131I uptake, absolute iodine uptake and serum protein bound 131I. Values for
serum PBI and serum thyroxine (T4) concentration were consistently increased averaging
more than twice found in normal pregnancy. The maximum binding capacity of the T4-
binding globulin(TBG) was variably affected and ranged between the values found in
normal controls and those found in the normal pregnancy. Values for the absolute of free
T4 in the serum were only moderately elevated since the proportion of free T4 was
moderately low, although not as low as in normal pregnancy [47].
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9. Clinical presentation of hyperthyroidism in gestational trophoblastic
disease
Hyperthyroidism has been reported as a complication of complete mole and persistent
trophoblastic disease, both metastatic and non metastatic [41]. Trophoblastic hyperthyroidism
has a widely divergent clinical pattern. Clinical hyperthyroidism is usually seen in patients
with extremely high levels of hCG [30]. The clinical scenario may vary from absence of
symptoms to thyroid storm [41,59]. Hyperthyroidism presents clinically as a physiological
state dominated by an increased metabolic rate.Myocardial contractility, heart rate, stroke
volume and ventricular size increase. Peripheral vascular resistance decreases in skin and
muscle The typical clinical findings include fatigue, weight loss, nervousness, excessive
sweating, heat intolerance, hyperactivity, tremor, weakness, hyperdynamic precordium,
diarrhoea, increased appetite, incapacitation [27], muscle weakness, tachycardia, minimal or
no enlargement of thyroid gland. Ophthalmopathy is not observed in this condition [41].
Cardiomyopathy is seen. Reflexes become hyper-reactive. [27].
Mild to moderate hyperthyroidism may be difficult to diagnose clinically during pregnancy
since normal parturients may experience symptoms such as heat intolerance, tachycardia,
emotional instability and vomiting. A resting tachycardia not slowed by the Valsalva ma‐
noeuvre is a strong indication of hyperthyroidism [60]. Several patients develop supra-
ventricular tachycardia and pulmonary oedema. The nausea, vomiting and toxaemia of
pregnancy that occur commonly in molar gestation may obscure the features of hyperthyr‐
oidism [28].
The development of biochemical and clinical thyrotoxicosis in patients with choriocarcinoma
depends upon the duration of the choriocarcinoma and the level of hCG [61]. In choriocarci‐
noma, the symptoms of metastasis to pelvis, lung, liver and brain may dominate the clinical
picture. There may be laboratory evidence of increased thyroid function without clinically
overt hyperthyroidism just as in hydatidiform mole [28].
During emergency surgery, the cardiovascular clinical manifestations of hyperthyroidism like
tachycardia can often be missed because they may be attributed to hypovolaemia [59].
10. Management of trophoblastic hyperthyroidism
Surgical removal of the hydatidiform mole in a hyperthyroid patient rapidly cures the
hyperthyroidism and should be performed as soon as possible [43,59]. Therapy of hyperthyr‐
oidism is not indicated in the vast majority of cases, since evacuation of the mole or chemo‐
therapy in the management of choriocarcinoma, removing high levels of hCG, cures the
hyperthyroidism. In those cases of severe symptoms, Lugol’s solution, intravenous iodine and
β blocking agents are indicated [7]. Therapy with potassium iodide given orally or sodium
iodide given intravenously(1 gm q8 hourly) will rapidly reduce serum free T4 and T3 levels.
Propranolol and other beta-adrenergic antagonist drugs are helpful to control tachycardia and
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other symptoms of sympathetic activation. Supportive measures such as fluid and electrolyte
replacement should be done as needed [28].
When hyperthyroidism occurs in the context of choriocarcinoma, case reports have demon‐
strated that the biomarkers of choriocarcinoma and thyroid function parallel the regression
and subsequent relapse of the tumor [3]. Several women with metastatic choriocarcinoma and
hyperthyroidism have achieved complete remission with chemotherapy. In the thyrotoxic
patient with choriocarcinoma, the hyperthyroidism should be treated by any of the usual
medical therapies [28]. The hyperthyroidism status secondary to molar disease rapidly
resolves after evacuation while that secondary to choriocarcinoma takes a longer time to
resolve [41].
Moskovitz JB and Bond MC reported the successful management of a case of thyroid storm in a 17year
old patient. She presented to a community hospital’s emergency department with history of palpitations
and tachycardia since one week. Βeta blockers and calcium channel blockers were administered. The
tachycardia partially responded. She was then referred to a tertiary centre for evaluation. There the
diagnosis of molar pregnancy was made using ultrasonogram and thyroid storm was diagnosed. She
was given intensive care support, treated with β-blockers and propylthiouracil. Surgical evacuation of
molar pregnancy was done and her symptoms soon resolved [62].
Walkington et al reported a case of a 21 year old woman who presented 2 months after a right salphin‐
gectomy for a ruptured ectopic pregnancy. She was breathless at rest, agitated and had a resting
tachycardia. Pelvis ultrasound and MRI showed a mass near right ovary. She was diagnosed with
choriocarcinoma with no evidence of metastasis. Serum hCG was 1.176x106IUL-1. Thyroid functions
showed her to be hyperthyroid with TSH <0.03 mIUL-1, free T4=73pmolL-1 and free T3=21.6pmolL-1. She
was commenced on carbimazole and propranolol. Her serum hCG and TFT measurements were as
follows (table 1). Her TFTs normalised in parallel with the fall in serum hCG. She was slowly weaned
off her anti-thyroid treatment and she became biochemically euthyroid at commencement of her third
cycle of chemotherapy [3].
Day HCG (IU l –1) TSH(mIU l– 1) FT4(pmol l –1) Carbimazole
0 791711 <0.03 73 40mgOD
7 156420 <0.03 15.2 40mgOD
21 19986 0.15 16.1 20mgOD
42 333 0.83 12.2 Stop
Abbreviations: FT4=free T4; HCG=human chorionic gonadotrophin; OD=once daily; TFT=thyroid function tests; TSH=thy‐
roid stimulating hormone
Table 1. Summary of serial HCG and TFT measurements
11. Perioperative management of trophoblastic hyperthyroidism
20% of cases of trophoblastic hyperthyroidism can develop severe perioperative complica‐
tions like high output cardiac failure secondary to thyrotoxicosis, thyroid storm, embolisa‐
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tion  of  pulmonary  arteries  by  trophoblastic  materials,  hypovolaemia,  disseminated
intravascular  coagulation,  pulmonary  oedema  secondary  to  severe  anaemia  and  acute
pulmonary distress secondary to any of these problems. They may require intensive care
support [1]. Hence the perioperative management and optimisation of hyperthyroid state
prior to surgical evacuation of the mole is very important [59].The perioperative manage‐
ment of hyperthyroidism focuses on the control of sympathetic activity so that cardiovascu‐
lar side-effects are not manifested [51].
11.1. Preoperative preparation
Preoperative optimisation with anti-thyroid and chemotherapeutic drugs is imperative to
reduce perioperative morbidity [59]. Every anaesthesiologist should be well aware of the
critical nature of perioperative complications that can be associated with a molar pregnancy.
A detailed pre-anaesthesia work up, preoperative optimisation of the patients’ thyroid and
volume status, planning and conducting anaesthesia carefully and being prepared for
advanced perioperative management are a must [63].
Preoperative evaluation of these patients should be based on history, physical examination
and laboratory testing [64]. The patient must be admitted to an intensive care unit preopera‐
tively. Blood count, electrolytes, blood gases, thyroid, hepatic, renal functions, β-hCG and
chest radiogram should be carefully evaluated [51]. Treatment has to be individualised. The
patient can be prepared for surgery with oral propylthiouracil (50-100mg qid), propranolol
(20mg tid), intravenous glucocorticoids and sodium iodide [27]. Some cases may require only
beta blockers whereas others may require in addition antithyroid drugs. Some may not require
any treatment if the hyperthyroidism is only biochemical and asymptomatic [41]. Dehydration
and anaemia if present should be corrected [25].
The  diagnosis  of  hyperthyroidism  in  molar  pregnancy  is  often  made  in  semi-urgent
conditions. Hence rapid stabilisation of the disease before surgery becomes important [45].
If there is no time to make the patient pharmacologically euthyroid, intravenous adminis‐
tration of iodine and β-adrenergic receptor blockers for emergency treatment of hyperthyr‐
oidism may be advisable [65]. These drugs, however, may be hazardous in patients who
have heart failure or pulmonary complications [64]. The role of plasmapheresis for the rapid
hormonal control in the preoperative period has been described. The use of plasmaphere‐
sis for the first time in the treatment of hyperthyroidism is reported in the 1970s. Erbil et
al  reported the  use  of  plasmapheresis  in  a  patient  with  severe  hyperthyroidism due  to
hydatidiform mole for the rapid control of hormonal levels [66]. A case of successful rapid
preoperative  preparation  by  3-4  sittings  of  plasmapheresis  of  a  patient  with  secondary
hyperthyroidism due to molar pregnancy has been described [67]. A study conducted by
Ozbey et  al  concluded that  plasmapheresis  is  a  treatment  option to  be  considered only
when anti-thyroid drugs are contraindicated [68].
11.2. Anaesthetic management
Sedation, monitored anaesthesia care, TIVA, general anaesthesia and spinal anaesthesia are
the various anaesthetic techniques that can be adopted for a case of evacuation of molar
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pregnancy [1,22,25,63]. Beta blockers for attenuation of sympathetic activity, emergency drugs
like lidocaine for ventricular arrhythmias, steroids and hypotensive agents like sodium
nitroprusside should be kept ready [69]. For patients with thyrotoxicosis due to molar
pregnancy, it is recommended that placement of invasive monitors like central venous
pressure be considered before induction of anaesthesia [1].
General anaesthesia may be the preferred technique in hypotensive bleeding patients sched‐
uled for emergency evacuation. Uterine relaxation caused by inhaled anaesthetics may
however increase blood loss [69]. Hence inhaled anaesthetics with known tocolytic qualities
such as halothane, enflurane and isoflurane should be used in lower concentrations [64]. A
nitrous oxide, opioid, muscle relaxant technique may also be preferred [51,64]. The safe use of
sevoflurane at 2.5 % concentrations has been reported by some authors without increasing the
chances of bleeding due to uterine relaxation [51].Drugs that minimally affect the cardiovas‐
cular system are the most rational choice in these patients [69]. Adequate premedication is
important to decrease unnecessary catecholamine release [69]. The anaesthesiologist should
avoid the administration of medications that stimulate the sympathetic nervous system and
should achieve an adequate depth of anaesthesia prior to surgical stimulation [69]. Medications
associated with tachycardia should be avoided e.g. atropine, ketamine.
In stable patients, spinal anaesthesia is preferable [69]. It can be used because
a. It is probably safe in patients with thyrotoxicosis.
b. It has favourable nontocolytic pharmacological properties.
c. It has preferable effects on the pulmonary system.
d. The sympathetic blockade associated with a regional technique may be desirable.
e. It is associated with a decrease in heart rate and blood pressure during surgery.
f. One can diagnose complications like thyroid storm at an earlier stage than when the
patient is sedated or under GA by maintaining the patients consciousness [64,69].
Intravenous fluids and blood must be administered judiciously as these patients have a
propensity to develop pulmonary oedema. Blood replacement may be required to treat
bleeding. Diuretics may be given intermittently [51].
Successful use of total intravenous anaesthesia (TIVA) has been reported for evacuation of
molar pregnancy with hyperthyroidism. E. Erturk et al reported the anaesthetic management
of a 25 year old woman having a hydatidiform mole with hyperthyroidism using TIVA
technique with propofol, remifentanil and esmolol infusion for controlling sympathetic
hyperactivity during surgery [26].
11.3. Postoperative care
Postoperatively, intensive care management may be indicated because most of the cardiopul‐
monary complications develop in the postoperative period [64]. Mechanical ventilatory
support must be provided if necessary. Treatment of thyroid storm, if it occurs, includes
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general supportive measures plus the administration of glucocorticoids, propylthiouracil,
sodium iodideand propranolol [27].
Solak M and Akturk G reported the successful perioperative management of a case of trophoblastic
hyperthyroidism. A 22 year old woman, in her third month of pregnancy, presented for emergency
evacuation. She had a history of vaginal bleeding and signs of hyperthyroidism like tremor, palpitation,
sweating and tachycardia for three weeks. Examination revealed an arterial blood pressure of 140/70
mm of Hg, a heart rate ranging from 110 to 130 beats per minute, a small thyroid nodule and signs of
hydatidiform mole in sonography and computerised tomography. Studies of thyroid function were
obtained: free triiodothyronine – 8.50pgml-1 (normal range 3.05-5.35 pgml-1) and free thyroxine –
5.56ngdl-1 (normal range 0.71-1.85 ngdl-1). Serum β-hCG was 961.96 mIUml-1 (normal range 0-5
mIUml-1). Serum thyroid stimulating hormone levels were within normal limits. The patient appeared
apprehensive, pale and shivering. She was administered intramusculardiazepam 5 mg 45 minutes
preoperatively. Arterial blood pressure came down to 110/70 mm of Hg and there was sinus tachycardia
(130 beats per minute). Spinal anaesthesia with 4 ml of 0.5% bupivacaine was administered at L3-4 level.
She lost 1000 – 1500 ml of blood intraoperatively and received approximately 100 ml of whole blood.
She was haemodynamically stable throughout the surgery which lasted for 30 minutes. Serum free T4
values were 4.13 and 1.25 ngml-1 on the 7th and 14th post-operative days respectively. She became
euthyroid few weeks after evacuation of the mole [64].
Puneet Khanna, Anil Kumar and Maya Dehran reported the successful perioperative management of a
44 year old female with hydatidiform mole. She had a history of irregular menstrual cycles since three
months. Preoperatively she appeared anxious, afebrile with a pulse rate of 116 per minute, blood pressure
of 120/80 mm of Hg and a respiratory rate of 20 per minute. The height of uterus was 14 weeks on per
abdominal examination. Haemoglobin was 13.1gms%. Thyroid function tests revealed TSH=0.03IU/
ml(0.03-5-5), T3=221IU/ml(70-200) and T4=14IU/ml(4.5-12.5). Ultra-sonogram of the abdomen
showed signs of an invasive hydatidiform mole. β-hCG levels were raised to 8,35,300mIUL-1. She was
put on tab. neomercazole 15 mgTDS, tab. propranolol 20 mgBD, Lugol’s iodine 4 drops TDS and inj.
dexamethasone 2mg 6th hourly.She was also started on chemotherapy with methotrexate on alternate
days and three cycles were given. Her β-hCG levels and thyroid functions were closely monitored. She
was posted for total abdominal hysterectomy and bilateral salphingo-oophorectomy but was postponed
due to persistent tachycardia reflecting an uncontrolled hyperthyroid state. The dose and frequency of
tab. propranolol was increased to 40mg 6th hourly. After three weeks her hyperthyroid state was partly
optimised(T4-9.94IU/ml and T3-0.014IU/ml) and she was accepted for the planned procedure.
Tab.diazepam 5mg was given on the night before and on the day of surgery. Patient was given combined
spinal epidural block in L3-4 space. Intravenous sedation was given with midazolam and fentanyl.
Intravenous dexamethasone was also given. Tabs.neomercazole, propranolol, amlodipine and dexame‐
thasone were continued post-operatively and Lugol’s iodine was stopped. Epidural analgesia with
morphine was provided postoperatively and on 3rd post-operative day thyroid function test started
showing improvement. On the 10th post-operative day, both β-hCG levels and thyroid function tests
normalised [59].
Laurent V and co-authors reported a case of successful perioperative management of a Senegalese
patient with hydatidiform mole. The patient had serum hCG levels of 900,000 IU. She was clinically
hyperthyroid  with  raised  T4  and  T3  levels  but  a  very  low  TSH  concentration.  She  was  given
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propranolol and carbimazole for 2 days. After that suction curettage was performed under general
anaesthesia.  Propranolol  was  again  administered  6  hours  after  surgery.  Thyroid  function  tests
returned  to  normal  levels  two  weeks  after  mole  removal  and  serum hCG concentrations  closely
paralleled those of free thyroxine [45].
12. Complications of hyperthyroidism in molar pregnancy
The two most serious maternal complications of untreated hyperthyroidism are heart failure,
being more common and thyroid storm [70]
12.1. Heart failure
High output cardiac failure secondary to the thyrotoxicosis can occur in the perioperative
period [43]. High output heart failure is caused by the myocardial effects of thyroxine.
Pulmonary hypertension which is correlated with untreated or inadequately controlled
hyperthyroidism can result in heart failure and pulmonary oedema [70]. Haemodynamic
problems like tachycardia, hypertension,increase in total blood volume,decrease in systemic
vascular resistance and increased cardiac output can result in cardiac decompensation and
arrhythmias [69]. Symptoms of high output cardiac failure include breathlessness at rest or on
exertion, exercise intolerance, fatigue, fluid retention and signs like tachycardia,tachyp‐
nea,raised jugular venous pressure, pulmonary rales,pleural effusion, peripheral oedema and
warm peripheries due to peripheral vasodilatation. Cardiac ultra-sound may show preserved
left ventricular ejection fraction [71].
Management of high output cardiac failure includes [72,73]
• Correction of the underlying hyperthyroidism.
• Carbimazole to alleviate thyrotoxicosis.
• Diuretics like frusemide to reverse the volume overload.
• Beta adrenoceptor blockers like esmolol and propranolol in particular to alleviate the
symptoms of hyperthyroidism and to control the heart rate.A cautious trial of ultrashort
acting beta blockers like esmolol can be done with invasive monitoring to detect the
occurrence of depressed myocardial contractility.
• Amiodarone to treat atrial fibrillation if present.
• Digoxin to slow down ventricular response rate in atrial fibrillation.
12.2. Thyrotoxicosis and thyroid storm
Thyroid storm occurs perioperatively in patients who have received either incomplete or no
treatment for the pre-existing hyperthyroidism [43,74]. Thyroid storm can lead to high output
cardiac failure [12].Cases of thyroid storm occurring in the intraoperative period have been
reported [75]. Severe thyrotoxicosis can occur even after surgical evacuation of the mole
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[76].Thyroid storm is a clinical diagnosis with manifestions like hyperpyrexia, severe dehy‐
dration, tachycardia,tachypnoea, diaphoresis, diarrhoea, atrial fibrillation, extreme anxiety,
altered consciousness and haemodynamic instability leading to cardiovascular collapse
[27,69]. Treatment of thyroid storm includes cooling blankets, intravenous hydration, glucose
and electrolyte replacement, oxygen, glucocorticoids like dexamethasone or hydrocortisone
intravenously, anti-thyroid drugs like oral/rectal propylthiouracil, methimazole, iodine in the
form of intravenous sodium iodide or oral Lugol’s iodine, β blockers like propranolol or
esmolol, plasma exchange, dantrolene and B-complex multivitamins [27].
12.3. Mortality and pulmonary morbidity
Few cases of mortality after surgical evacuation in patients with molar pregnancy have been
described [63,12] and some of them were hyperthyroid [63,77]. Respiratory complications
including pulmonary oedema and acute respiratory distress syndrome (ARDS) were observed
in these cases [63,77]. Few authors have also reported successful intensive treatment of ARDS
occurring in hyperthyroid patients with molar pregnancy [74].
Severe thyrotoxicosis has been reported after commencing treatment for gestational trophoblastic
disease. A 53-year-old woman developed profound cardiovascular instability one day after surgical
evacuation of a complete hydatidiform mole. She was not known to have pre-existing thyroid disease but
investigations confirmed thyrotoxicosis [76]
Carrasco C and Cotoras J reported an interesting case of molar pregnancy with complications of
hyperthyroidism. An 18 year old woman was admitted with a history of four days of cardiac failure with
acute pulmonary oedema, high blood pressure, left ventricular dilatation and moderate to severe systolic
dysfunction. Twenty four hours after admission she had a miscarriage expelling a mole. The diagnosis
of hyperthyroidism caused by a mole and early preeclampsia was confirmed and the patient was managed
with diuretics and dopamine. Symptoms abated. Thyroid function tests, cardiac function and size
returned to normal values [78].
Hershman JM and Higgins HP reported a case of a 29 year old, 4 months pregnant Italian woman. She
came complaining of shortness of breath, extreme fatigue, nervousness and heat intolerance. Since the
past one week she had severe nausea and vomiting and vaginal spotting. On examination, she appeared
anxious with soft, warm skin, fine hair and sweaty palms. The pulse rate was 110 per minute and regular,
the blood pressure was 150/60 mm of Hg. The thyroid gland was slightly enlarged. Grade 2 ejection
murmur was heard over the pulmonary area and a ventricular gallop was heard over the apex. The
peripheral pulses were bounding. Ultrasonography showed signs of a molar pregnancy. The protein
bound iodine(PBI)level was 22.7 mμg, serum thyroxine-iodine was 18mμg/100ml, 24 hour uptake of
radioactive iodine was 75% and serum free thyroxine was raised: 14.8 mμg/100ml (normal 3-5mμg /
100 ml). Carbimazole 60mg per day was started. On the evening of the 7th day, supraventricular
tachycardia suddenly developed and acute pulmonary oedema ensued shortly. She was treated with nasal
oxygen, digoxin, ouabain and diuretics. A plasmapheresis was performed and packed red cells were
transfused. The next day, there was a rapid tachycardia but no evidence of congestive heart failure. On
the 8th day, a total abdominal hysterectomy was performed. Two further episodes of pulmonary oedema
treated successfully with digoxin, occurred on the first and third post-operative days. She improved
Thyroid Disorders - Focus on Hyperthyroidism262
markedly. Tachycardia came back to normal; radio iodine uptake and PBI came back to normal by 14
days [48].
An unusual case of a 13 year old Caucasian patient with a complete hydatidiform mole was reported
wherein during anaesthesia induction, she presented symptoms compatible with a thyrotoxic crisis. The
patient had complaints of amenorrhoea, abdominal pain and vaginal bleeding. She was tachypnoeic,
tachycardic, hypertensive, pale and dehydrated. Her haemoglobin was 9.9gm/dl, serum TSH was
0.009mIU/ml (normal 0.35 – 5.5). HCG levels were higher than 400,000 IU/L. She underwent chest,
abdominal and pelvic CT scanning with iodinated contrast and was scheduled to undergo a uterine
curettage. General anaesthesia was administered via intravenous induction with fentanyl, propofol,
endotracheal intubation and muscle relaxation with atracurium. After oro-tracheal intubation, she
developed sinus tachycardia (170 beats per minute), hypertension (160/120 mm of Hg), hypercarbia (52
mm of Hg) and acute pulmonary oedema. She was diagnosed to be in a thyrotoxic crisis. She was treated
with intravenous esmolol and sodium nitroprusside 75μg/kg/min respectively with satisfactory response
and transferred to the ICU and managed there till she became haemodynamically stable. The use of
iodinated substances can trigger thyrotoxic crisis (Jod-Basedow phenomenon) and in this case, the
iodinated contrast used to perform scan preoperatively could have contributed to the development of
thyrotoxic crisis [79].
13. Conclusions
Trophoblastic tumors are associated with biochemical and clinical hyperthyroidism. Hence
measurement of thyroid function in patients with gestational trophoblastic disease is impor‐
tant. Thyroid function normalises rapidly with treatment of the underlying gestational
trophoblastic disease and consequent fall in hCG levels. Treatment of gestational trophoblastic
disease includes surgical evacuation or chemotherapy. Hydatidiform mole with hyperthyr‐
oidism is a perioperative challenge. All patients should be stabilised with β-blockers and anti-
thyroid medications prior to induction of anaesthesia for surgical evacuation. Vigilant
monitoring and intensive care should be done perioperatively to watch for the occurrence of
cardiopulmonary complications or thyroid storm.
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